<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName archivearticle3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Genet Genomic Med</journal-id><journal-id journal-id-type="iso-abbrev">Mol Genet Genomic Med</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2324-9269</journal-id><journal-id journal-id-type="publisher-id">MGG3</journal-id><journal-title-group><journal-title>Molecular Genetics &amp; Genomic Medicine</journal-title></journal-title-group><issn pub-type="epub">2324-9269</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6305680</article-id><article-id pub-id-type="doi">10.1002/mgg3.425</article-id><article-id pub-id-type="publisher-id">MGG3425</article-id><article-categories><subj-group subj-group-type="overline"><subject>Clinical Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Clinical Reports</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Hemophilia B in a female with intellectual disability caused by a deletion of Xq26.3q28 encompassing the F9 </plain></SENT>
</text></SecTag></article-title><alt-title alt-title-type="left-running-head">STOOF et al.</alt-title></title-group><contrib-group><contrib id="mgg3425-cr-0001" contrib-type="author"><name><surname>Stoof</surname><given-names>Sara C. M.</given-names></name><xref ref-type="aff" rid="mgg3425-aff-0001">
<sup>1</sup>
</xref><xref ref-type="author-notes" rid="mgg3425-note-1001">
<sup>†</sup>
</xref></contrib><contrib id="mgg3425-cr-0002" contrib-type="author"><name><surname>Kersseboom</surname><given-names>Rogier</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7824-8941</contrib-id><xref ref-type="aff" rid="mgg3425-aff-0002">
<sup>2</sup>
</xref><xref ref-type="aff" rid="mgg3425-curr-0001">
<sup>3</sup>
</xref><xref ref-type="author-notes" rid="mgg3425-note-1001">
<sup>†</sup>
</xref></contrib><contrib id="mgg3425-cr-0003" contrib-type="author"><name><surname>de Vries</surname><given-names>Femke A. T.</given-names></name><xref ref-type="aff" rid="mgg3425-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="mgg3425-cr-0004" contrib-type="author"><name><surname>Kruip</surname><given-names>Marieke J. H. A.</given-names></name><xref ref-type="aff" rid="mgg3425-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="mgg3425-cr-0005" contrib-type="author"><name><surname>Kievit</surname><given-names>Anneke J. A.</given-names></name><xref ref-type="aff" rid="mgg3425-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="mgg3425-cr-0006" contrib-type="author" corresp="yes"><name><surname>Leebeek</surname><given-names>Frank W. G.</given-names></name><address><email>f.leebeek@erasmusmc.nl</email></address><xref ref-type="aff" rid="mgg3425-aff-0001">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="mgg3425-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Department of Hematology</named-content>
<institution>Erasmus University Medical Centre</institution>
<named-content content-type="city">Rotterdam</named-content>
<country country="NL">The Netherlands</country>
</aff><aff id="mgg3425-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Department of Clinical Genetics</named-content>
<institution>Erasmus University Medical Centre</institution>
<named-content content-type="city">Rotterdam</named-content>
<country country="NL">The Netherlands</country>
</aff><aff id="mgg3425-curr-0001"><label><sup>3</sup></label>Present address:
<named-content content-type="organisation-division">Medical Service</named-content>
<institution>Tragel Zorg</institution>
<named-content content-type="city">Clinge</named-content>
<country country="NL">The Netherlands</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Frank W. G. Leebeek, Erasmus University Medical Centre, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands.<break/>
Email: <email>f.leebeek@erasmusmc.nl</email><break/></corresp><fn fn-type="equal" id="mgg3425-note-1001"><label>†</label><p><text><SENT sid="1" pm="."><plain>These authors contributed equally and share first authorship. </plain></SENT>
</text></p></fn></author-notes><pub-date pub-type="epub"><day>27</day><month>9</month><year>2018</year></pub-date><pub-date pub-type="collection"><month>11</month><year>2018</year></pub-date><volume>6</volume><issue>6</issue><issue-id pub-id-type="doi">10.1002/mgg3.2018.6.issue-6</issue-id><fpage>1220</fpage><lpage>1224</lpage><history><date date-type="received"><day>27</day><month>2</month><year>2018</year></date><date date-type="rev-recd"><day>28</day><month>4</month><year>2018</year></date><date date-type="accepted"><day>05</day><month>6</month><year>2018</year></date></history><permissions><copyright-statement content-type="article-copyright">© 2018 The Authors. <italic>Molecular Genetics &amp; Genomic Medicine</italic> published by Wiley Periodicals, Inc.</copyright-statement><license license-type="creativeCommonsBy"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:MGG3-6-1220.pdf"/><abstract id="mgg3425-abs-0001"><title><text><SENT sid="2" pm="."><plain>Abstract </plain></SENT>
</text></title><sec id="mgg3425-sec-0001"><title><text><SENT sid="3" pm="."><plain>Background </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="4" pm="."><plain>Hemophilia B is an X‐linked recessive disorder caused by mutations in the F9 on Xq27.1. </plain></SENT>
<SENT sid="5" pm="."><plain>Mainly males are affected but about 20% of female carriers have clotting factor IX activity below 0.40 IU/ml and bleeding problems. </plain></SENT>
<SENT sid="6" pm="."><plain>Fragile‐X syndrome (FMR1) and FRAXE syndrome (AFF2) are well‐known causes of X‐linked recessive intellectual disability. </plain></SENT>
<SENT sid="7" pm="."><plain>Simultaneous deletion of both FMR1 and AFF2 in males results in severe intellectual disability. </plain></SENT>
<SENT sid="8" pm="."><plain>In females the phenotype is more variable. </plain></SENT>
<SENT sid="9" pm="."><plain>We report a 19‐year‐old female with severe intellectual disability and a long‐standing bleeding history. </plain></SENT>
</text></SecTag></p></sec><sec id="mgg3425-sec-0002"><title><text><SENT sid="10" pm="."><plain>Methods </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="11" pm="."><plain>A SNP array analysis (Illumina Human Cyto 12‐SNP genotyping array) and sequencing of F9 were performed. </plain></SENT>
<SENT sid="12" pm="."><plain>Laboratory tests were performed to evaluate the bleeding diathesis. </plain></SENT>
</text></SecTag></p></sec><sec id="mgg3425-sec-0003"><title><text><SENT sid="13" pm="."><plain>Results </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="14" pm="."><plain>Our patient was diagnosed with mild hemophilia B after finding an 11 Mb deletion of Xq26.3q28 that included the following genes among others IDS,SOX3,FMR1,AFF2, and F9. </plain></SENT>
</text></SecTag></p></sec><sec id="mgg3425-sec-0004"><title><text><SENT sid="15" pm="."><plain>Conclusion </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="16" pm="."><plain>The case history demonstrates that a severe bleeding tendency suggestive of a hemostasis defect in patients with intellectual disability warrants careful hematological and genetic work‐up even in the absence of a positive family history. </plain></SENT>
</text></SecTag></p></sec></abstract><SecTag type="KEYWORD"><kwd-group kwd-group-type="author-generated"><kwd id="mgg3425-kwd-0001"><italic>F9</italic></kwd><kwd id="mgg3425-kwd-0002">hemophilia B</kwd><kwd id="mgg3425-kwd-0003">intellectual disability</kwd><kwd id="mgg3425-kwd-0004">X‐chromosomal deletion</kwd></kwd-group></SecTag><counts><fig-count count="2"/><table-count count="0"/><page-count count="5"/><word-count count="2888"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>mgg3425</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>November 2018</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.5.4 mode:remove_FC converted:25.12.2018</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="mgg3425-cit-1001">
<string-name>
<surname>Stoof</surname>
<given-names>SCM</given-names>
</string-name>, <string-name>
<surname>Kersseboom</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>de Vries</surname>
<given-names>FAT</given-names>
</string-name>, <string-name>
<surname>Kruip</surname>
<given-names>MJHA</given-names>
</string-name>, <string-name>
<surname>Kievit</surname>
<given-names>AJA</given-names>
</string-name>, <string-name>
<surname>Leebeek</surname>
<given-names>FWG</given-names>
</string-name>. <article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Hemophilia B in a female with intellectual disability caused by a deletion of Xq26.3q28 encompassing the F9 </plain></SENT>
</text></SecTag></article-title>. <source xml:lang="en">Mol Genet Genomic Med</source>. <year>2018</year>;<volume>6</volume>:<fpage>1220</fpage>–<lpage>1224</lpage>. <pub-id pub-id-type="doi">10.1002/mgg3.425</pub-id>
</mixed-citation>
</p></notes></front><body><SecTag type="INTRO"><sec id="mgg3425-sec-0005"><label>1</label><title><text><SENT sid="1" pm="."><plain>INTRODUCTION </plain></SENT>
</text></title><p><text><SENT sid="2" pm="."><plain>Hemophilia B is an X‐linked recessive bleeding disorder caused by mutations in the F9 (OMIM 300746) on Xq27.1 resulting in reduced factor IX (FIX) activity. </plain></SENT>
<SENT sid="3" pm="."><plain>It occurs in about 2.8 cases per 100.000 males (Berntorp &amp; Shapiro, 2012). </plain></SENT>
<SENT sid="4" pm="."><plain>Patients may experience surgery or trauma‐induced bleeding and, if more severe, spontaneous bleedings, for which they can be treated prophylactically or on‐demand with FIX concentrate. </plain></SENT>
<SENT sid="5" pm="."><plain>Although mainly males are affected, about 20% of female carriers have FIX activity below 0.40 IU/ml (Konkle, Josephson, &amp; Nakaya Fletcher, 1993), which is thought to be caused by skewed X‐inactivation. </plain></SENT>
<SENT sid="6" pm="."><plain>Mutations in the F9 occur de novo in up to half of the families. </plain></SENT>
<SENT sid="7" pm="."><plain>Point mutations are the most frequent cause of hemophilia B, deletions and duplications account for only 3% (Li, Miller, Payne, &amp; Craig Hooper, 2013). </plain></SENT>
<SENT sid="8" pm="."><plain>Approximately 30% of affected males have no family history of hemophilia B (Sommer, Scaringe, &amp; Hill, 2001). </plain></SENT>
<SENT sid="9" pm="."><plain>Here, we report a 19‐year‐old female with severe intellectual disability (ID) and a long‐standing bleeding history, who was diagnosed with mild hemophilia B after finding a large Xq‐deletion that included the F9. </plain></SENT>
</text></p><sec id="mgg3425-sec-0006"><label>1.1</label><title><text><SENT sid="10" pm="."><plain>Ethical compliance </plain></SENT>
</text></title><p><text><SENT sid="11" pm="."><plain>This case study was not subject to the Medical Research Involving Human Subjects Act (WMO) as it only involved file research and no additional diagnostic tests were performed. </plain></SENT>
<SENT sid="12" pm="."><plain>Informed consent of the legal representatives of our patient was obtained. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="METHODS,RESULTS"><sec id="mgg3425-sec-0007"><label>2</label><title><text><SENT sid="13" pm="."><plain>METHODS AND RESULTS </plain></SENT>
</text></title><p><text><SENT sid="14" pm="."><plain>The patient was the third child of healthy unrelated parents and had two healthy sisters. </plain></SENT>
<SENT sid="15" pm="."><plain>There was no bleeding disorder known in the family. </plain></SENT>
<SENT sid="16" pm="."><plain>She was born at 41 weeks after spontaneous delivery, weighing 3,450 g (50th percentile). </plain></SENT>
<SENT sid="17" pm="."><plain>Apgar scores were 10 and 10 at 1 and 5 min, respectively. </plain></SENT>
<SENT sid="18" pm="."><plain>After birth she was hypotonic and had feeding difficulties. </plain></SENT>
<SENT sid="19" pm="."><plain>She had severe developmental delay already apparent during infancy, severely impaired speech development, and did not walk until the age of 10 years. </plain></SENT>
<SENT sid="20" pm="."><plain>Her past medical history was remarkable because of a long‐standing history of easy bruising and several severe bleeding episodes. </plain></SENT>
<SENT sid="21" pm="."><plain>At age 2 she fell from a chair and developed a large head wound. </plain></SENT>
<SENT sid="22" pm="."><plain>Ten days after initial healing, a rebleeding occurred. </plain></SENT>
<SENT sid="23" pm="."><plain>At 12 years she fell off the stairs and developed a severe perineal bleed for which she was admitted to the hospital in hypovolemic shock. </plain></SENT>
<SENT sid="24" pm="."><plain>She received multiple blood transfusions and rebleeding occurred twice with 1‐week interval. </plain></SENT>
<SENT sid="25" pm="."><plain>She also had a tooth extraction and another head trauma with prolonged bleeding. </plain></SENT>
<SENT sid="26" pm="."><plain>Occasionally she had large hematomas mostly on the abdomen. </plain></SENT>
<SENT sid="27" pm="."><plain>No muscle or joint bleeds occurred. </plain></SENT>
<SENT sid="28" pm="."><plain>No detailed investigation for a bleeding disorder was performed. </plain></SENT>
</text></p><p><text><SENT sid="29" pm="."><plain>At 19 years of age she was seen at the department of clinical genetics (Figure 1). </plain></SENT>
<SENT sid="30" pm="."><plain>She had a length of 158 cm (−1.8 SD) and a head circumference of 54.6 cm (−0.5 SD). </plain></SENT>
<SENT sid="31" pm="."><plain>She was obese with a good appetite and lack of satiety especially during childhood. </plain></SENT>
<SENT sid="32" pm="."><plain>Clinical examination revealed abnormal fat distribution mainly localized on the abdomen, thighs and buttocks. </plain></SENT>
<SENT sid="33" pm="."><plain>She had deep set eyes, periorbital fullness, mild upslanting eyelids, a prominent chin, large ears, small hands 15.7 cm (−3 SD), slight tapering of the fingers, soft skin of the hands, joint hyperlaxity of the hands and small feet (Figure 1). </plain></SENT>
<SENT sid="34" pm="."><plain>On neurological examination she was severely hypotonic, had a stumbling gait and dysarthria. </plain></SENT>
<SENT sid="35" pm="."><plain>She communicated using few words and gestures. </plain></SENT>
<SENT sid="36" pm="."><plain>She has intermittent exotropia. </plain></SENT>
<SENT sid="37" pm="."><plain>Also, she still has urinary and fecal incontinence. </plain></SENT>
<SENT sid="38" pm="."><plain>She has primary amenorrhea but normal secondary sex characteristics, without signs of premature ovarian failure (POF) on endocrinological evaluation (LH 4.8 U/L; FSH 4.9 U/L; estrogen 93 pmol/L). </plain></SENT>
</text></p><fig fig-type="Figure" xml:lang="en" id="mgg3425-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p><text><SENT sid="39" pm="."><plain>Pictures of the patient. </plain></SENT>
<SENT sid="40" pm="."><plain>(a) Notice deep set eyes, periorbital fullness, wide nasal root, thin upper vermilion border, and prominent chin. </plain></SENT>
<SENT sid="41" pm="."><plain>(b) Notice small hands with smooth skin and slight tapering of the fingers </plain></SENT>
</text></p></caption><graphic id="nlm-graphic-3" xlink:href="MGG3-6-1220-g001"/></fig><p><text><SENT sid="42" pm="."><plain>At 2 years of age, chromosome analysis showed a normal female karyotype. </plain></SENT>
<SENT sid="43" pm="."><plain>Metabolic blood‐ and urine analyses, including sialotransferrines, were normal. </plain></SENT>
<SENT sid="44" pm="."><plain>DNA analyses for Prader‐Willi‐ and Fragile‐X‐syndrome were both negative. </plain></SENT>
<SENT sid="45" pm="."><plain>An MRI of the brain at the age of 3 showed a thin corpus callosum at the splenium, but no other structural abnormalities. </plain></SENT>
<SENT sid="46" pm="."><plain>Recently, SNP array analysis (Illumina Human Cyto 12‐SNP genotyping array) was performed which showed an 11 Mb interstitial deletion of the chromosomal region Xq26.3q28 [arr Xq26.3q28(137,097,172–148,991,868)]. </plain></SENT>
<SENT sid="47" pm="."><plain>The region contains 118 annotated genes (Figure 2). </plain></SENT>
<SENT sid="48" pm="."><plain>The OMIM disease‐associated genes located in this region are IDS (OMIM 300823), SOX3 (OMIM 313430), FMR1 (OMIM 309550), AFF2 (OMIM 300806), and F9 (Figure 2). </plain></SENT>
<SENT sid="49" pm="."><plain>The Xq26.3q28 deletion was either de novo or due to (germline) mosaicism in one of the parents. </plain></SENT>
<SENT sid="50" pm="."><plain>FISH analysis in both the patient and her parents did not reveal structural X‐chromosome abnormalities. </plain></SENT>
</text></p><fig fig-type="Figure" xml:lang="en" id="mgg3425-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p><text><SENT sid="51" pm="."><plain>Schematic representation of X‐chromosome and genes in the Xq26‐q28 region. </plain></SENT>
<SENT sid="52" pm="."><plain>Region of deletion in our patient is highlighted by the red box. </plain></SENT>
<SENT sid="53" pm="."><plain>The OMIM disease‐associated genes in green and all UCSC annotated genes in blue within the deletion region (hg19) are shown. </plain></SENT>
<SENT sid="54" pm="."><plain>Image was adapted from <ext-link ext-link-type="uri" xlink:href="http://genome.ucsc.edu/cgi-bin/hgTracks">http://genome.ucsc.edu/cgi-bin/hgTracks</ext-link> </plain></SENT>
</text></p></caption><graphic id="nlm-graphic-5" xlink:href="MGG3-6-1220-g002"/></fig><p><text><SENT sid="55" pm="."><plain>Because of the bleeding diathesis and potential FIX defect based on the F9 deletion, the patient was referred by the clinical geneticist to the hemophilia treatment center. </plain></SENT>
<SENT sid="56" pm="."><plain>Laboratory results were normal for PFA, VWF:Ag, VWF:CB, VWF:Act, and PT. </plain></SENT>
<SENT sid="57" pm="."><plain>FIX was 0.20 IU/ml (normal value: 0.60–1.40 IU/ml). </plain></SENT>
<SENT sid="58" pm="."><plain>Surprisingly, there was a normal APTT (29 s, normal value 22–32 s), most likely due to a FVIII of 1.59 IU/ml (normal value: 0.60–1.40 IU/ml). </plain></SENT>
</text></p><p><text><SENT sid="59" pm="."><plain>She scored a 5 on the ISTH (International Society on Thrombosis and Hemostasis) Bleeding Assessment Tool. </plain></SENT>
<SENT sid="60" pm="."><plain>Based on her history and the laboratory results she was diagnosed as a hemophilia B carrier due to a F9 deletion. </plain></SENT>
</text></p><p><text><SENT sid="61" pm="."><plain>To exclude the presence of a second mutation on the other F9‐allele contributing to the phenotype, we performed sequence analysis of F9. </plain></SENT>
<SENT sid="62" pm="."><plain>This did not reveal any additional mutations. </plain></SENT>
<SENT sid="63" pm="."><plain>In rare cases moderate to severe hemophilia B has been seen in females and this has generally been ascribed to skewed X‐inactivation. </plain></SENT>
<SENT sid="64" pm="."><plain>To test for skewed X‐inactivation we analyzed urine for the presence of abnormal mucopolysaccharide patterns indicative of decreased IDS activity in Hunter syndrome (mucopolysaccharidosis type 2, MPS2). </plain></SENT>
<SENT sid="65" pm="."><plain>Additionally, we performed pituitary function evaluation (thyroid axis, growth hormone axis, and prolactin) and tested X‐inactivation in peripheral blood leukocytes using the analysis of the methylation status of the AR locus located in Xq12 (Allen, Zoghbi, Moseley, Rosenblatt, &amp; Belmont, 1992). </plain></SENT>
<SENT sid="66" pm="."><plain>No evidence for MPS2, pituitary dysfunction or skewed X‐inactivation was found. </plain></SENT>
</text></p></sec></SecTag><SecTag type="DISCUSS"><sec id="mgg3425-sec-0008"><label>3</label><title><text><SENT sid="67" pm="."><plain>DISCUSSION </plain></SENT>
</text></title><p><text><SENT sid="68" pm="."><plain>We report a 19‐year‐old female with severe intellectual disability (ID) and a long‐standing bleeding history, who was diagnosed with mild hemophilia B after finding a large Xq‐deletion that included the F9. </plain></SENT>
<SENT sid="69" pm="."><plain>This demonstrates that a severe bleeding tendency suggestive of a hemostasis defect in patients with intellectual disability warrants careful hematological and genetic work‐up even in the absence of a positive family history. F9 deletions can range from a few base pairs to several megabases and are found in approximately 3% of patients with hemophilia B. </plain></SENT>
<SENT sid="70" pm="."><plain>In our patient the hemizygous state of F9 likely caused mild hemophilia B as is well known in carriers of hemophilia (Nisen &amp; Waber, 1989). </plain></SENT>
<SENT sid="71" pm="."><plain>In accordance with a previous study, we could not demonstrate skewed X‐inactivation (Orstavik, Scheibel, Ingerslev, &amp; Schwartz, 2000). </plain></SENT>
<SENT sid="72" pm="."><plain>The inability to consistently demonstrate skewed X‐inactivation in hemophilia B carriers most likely reflects the usage of blood for these studies. </plain></SENT>
<SENT sid="73" pm="."><plain>A more reliable way to study the role of the X‐inactivation pattern in hemophilia B carriers would be to directly examine liver tissue, which is non‐ethical. </plain></SENT>
<SENT sid="74" pm="."><plain>Although skewed X‐inactivation is the most important hypothesis to explain variability in FIX activity in carriers, it cannot be excluded that other factors (including genetic) influence factor IX activity in carriers. </plain></SENT>
</text></p><p><text><SENT sid="75" pm="."><plain>Several large deletions of the Xq26‐q28 region have been reported that partly overlap with our patient's deletion. </plain></SENT>
<SENT sid="76" pm="."><plain>The other OMIM disease‐associated genes located in the deletion found in our patient include IDS (mucopolysaccharidosis type 2, MPS2) (Johnson, van Diggelen, Dajnoki, &amp; Bodamer, 2013), SOX3 (related to pituitary development) (Rizzoti et al., 2004), FMR1 (Fragile‐X syndrome), and AFF2 (FRAXE syndrome) (Cordts, Christofolini, Dos Santos, Bianco, &amp; Barbosa, 2011; Moore et al., 1999). </plain></SENT>
<SENT sid="77" pm="."><plain>A unique feature in our patient was that in addition to the genes FMR1, AFF2, and IDS, F9 was deleted. </plain></SENT>
<SENT sid="78" pm="."><plain>Hemizygosity for IDS has rarely been shown to result in MPS2 in females (Clarke et al., 1992). </plain></SENT>
<SENT sid="79" pm="."><plain>In our patient no evidence for MPS2 was found. </plain></SENT>
<SENT sid="80" pm="."><plain>Duplications of the SOX3 and polyalanine tract expansions of the C‐terminal domain of SOX3 have been linked to septo‐optic dysplasia, ID, and panhypopituitarism. </plain></SENT>
<SENT sid="81" pm="."><plain>In accordance with a previous publication reporting SOX3 deletion, we found no evidence for pituitary dysfunction or visual problems (Helle et al., 2013). </plain></SENT>
<SENT sid="82" pm="."><plain>A more recent paper suggested that the deletion of SOX3 may even be causative of mild intellectual disability (Jourdy et al., 2016). </plain></SENT>
<SENT sid="83" pm="."><plain>Deletion of FMR1 and AFF2 has been shown to cause fragile X syndrome and probably FRAXE‐syndrome (Coffee et al., 2008; Sahoo et al., 2011). </plain></SENT>
<SENT sid="84" pm="."><plain>Simultaneous deletion of both FMR1 and AFF2 in males results in severe ID and variable other features including hypotonia, epilepsy, obesity, and autism (Coffee et al., 2008). </plain></SENT>
<SENT sid="85" pm="."><plain>In females the phenotype is more variable: some had ID, obesity, and primary amenorrhea, whereas others had primary amenorrhea or POF without ID (Coffee et al., 2008; Mercer et al., 2013). </plain></SENT>
<SENT sid="86" pm="."><plain>The variability of the phenotype in females may be related to differences in X‐inactivation patterns. </plain></SENT>
<SENT sid="87" pm="."><plain>This is supported by the finding that within families there may be marked variability in the grade of intellectual ability and age of onset of POF (Fimiani et al., 2006; Mercer et al., 2013). </plain></SENT>
<SENT sid="88" pm="."><plain>It remains unclear why deletion of the Xq26.3q28 region is involved with POF. </plain></SENT>
<SENT sid="89" pm="."><plain>One theory is that FMR1 is involved, because premutations in FMR1 are associated with POF. </plain></SENT>
<SENT sid="90" pm="."><plain>It is unclear whether deletion of FMR1 has a similar effect. </plain></SENT>
<SENT sid="91" pm="."><plain>An alternative explanation is that other genes within the Xq26.3q28 region are involved. </plain></SENT>
</text></p><p><text><SENT sid="92" pm="."><plain>The case history demonstrates that a severe bleeding tendency suggestive of a hemostasis defect in patients with intellectual disability warrants careful hematological and genetic work‐up even in the absence of a positive family history. </plain></SENT>
<SENT sid="93" pm="."><plain>Especially, since numerous genetic conditions are characterized by both intellectual disability and increased bleeding tendency and a bleeding disorder may be recognized less easily in people with intellectual disability (as is the case for many medical conditions). </plain></SENT>
</text></p></sec></SecTag><SecTag type="COMP_INT"><sec id="mgg3425-sec-0010"><title><text><SENT sid="94" pm="."><plain>CONFLICT OF INTEREST </plain></SENT>
</text></title><p><text><SENT sid="95" pm="."><plain>The authors declare no conflicts of interest. </plain></SENT>
</text></p></sec></SecTag><SecTag type="AUTH_CONT"><sec id="mgg3425-sec-0011"><title><text><SENT sid="96" pm="."><plain>AUTHOR CONTRIBUTION </plain></SENT>
</text></title><p><text><SENT sid="97" pm="."><plain>RK, FWGL, and JAK clinically reviewed the patient and wrote the manuscript. </plain></SENT>
<SENT sid="98" pm="."><plain>SCMS performed research and wrote the manuscript. </plain></SENT>
<SENT sid="99" pm="."><plain>FATV performed analyses and critically revised the manuscript. </plain></SENT>
<SENT sid="100" pm="."><plain>MJHAK interpreted the data and critically revised the manuscript. </plain></SENT>
<SENT sid="101" pm="."><plain>All authors approved the final version of the manuscript. </plain></SENT>
</text></p></sec></SecTag><sec id="mgg3425-sec-0012"><title><text><SENT sid="102" pm="."><plain>PATIENT CONSENT </plain></SENT>
</text></title><p><text><SENT sid="103" pm="."><plain>Informed consent of the parents was obtained. </plain></SENT>
</text></p></sec></body><back><SecTag type="ACK_FUND"><ack id="mgg3425-sec-0009"><title>ACKNOWLEDGMENTS</title><p><text4fund><text><SENT sid="104" pm="."><plain>The authors thank the patient and her family for granting us permission to share her story and pictures within this publication. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="REF"><ref-list content-type="cited-references" id="mgg3425-bibl-0001"><title>REFERENCES</title><ref id="mgg3425-bib-0001"><text><SENT sid="105" pm="."><plain>  Allen, R. </plain></SENT>
<SENT sid="106" pm="."><plain>C. ,  Zoghbi, H. </plain></SENT>
<SENT sid="107" pm="."><plain>Y. ,  Moseley, A. </plain></SENT>
<SENT sid="108" pm="."><plain>B. ,  Rosenblatt, H. </plain></SENT>
<SENT sid="109" pm="."><plain>M. , &amp;  Belmont, J. </plain></SENT>
<SENT sid="110" pm="."><plain>W.  (1992). Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen‐receptor gene correlates with X chromosome inactivation. American Journal of Human Genetics, 51, 1229–1239.1281384 </plain></SENT>
</text></ref><ref id="mgg3425-bib-0002"><text><SENT sid="111" pm="."><plain>  Berntorp, E. , &amp;  Shapiro, A. </plain></SENT>
<SENT sid="112" pm="."><plain>D.  (2012). Modern haemophilia care. Lancet, 379, 1447–1456. 10.1016/S0140-6736(11)61139-2 22456059 </plain></SENT>
</text></ref><ref id="mgg3425-bib-0003"><text><SENT sid="113" pm="."><plain>  Clarke, J. </plain></SENT>
<SENT sid="114" pm="."><plain>T. ,  Wilson, P. </plain></SENT>
<SENT sid="115" pm="."><plain>J. ,  Morris, C. </plain></SENT>
<SENT sid="116" pm="."><plain>P. ,  Hopwood, J. </plain></SENT>
<SENT sid="117" pm="."><plain>J. ,  Richards, R. </plain></SENT>
<SENT sid="118" pm="."><plain>I. ,  Sutherland, G. </plain></SENT>
<SENT sid="119" pm="."><plain>R. , &amp;  Ray, P. </plain></SENT>
<SENT sid="120" pm="."><plain>N.  (1992). Characterization of a deletion at Xq27‐q28 associated with unbalanced inactivation of the nonmutant X chromosome. American Journal of Human Genetics, 51, 316–322.1642233 </plain></SENT>
</text></ref><ref id="mgg3425-bib-0004"><text><SENT sid="121" pm="."><plain>  Coffee, B. ,  Ikeda, M. ,  Budimirovic, D. </plain></SENT>
<SENT sid="122" pm="."><plain>B. ,  Hjelm, L. </plain></SENT>
<SENT sid="123" pm="."><plain>N. ,  Kaufmann, W. </plain></SENT>
<SENT sid="124" pm="."><plain>E. , &amp;  Warren, S. </plain></SENT>
<SENT sid="125" pm="."><plain>T.  (2008). Mosaic FMR1 deletion causes fragile X syndrome and can lead to molecular misdiagnosis: A case report and review of the literature. American Journal of Medical Genetics. </plain></SENT>
<SENT sid="126" pm="."><plain>Part A, 146A, 1358–1367. 10.1002/(ISSN)1552-4833 18412117 </plain></SENT>
</text></ref><ref id="mgg3425-bib-0005"><text><SENT sid="127" pm="."><plain>  Cordts, E. </plain></SENT>
<SENT sid="128" pm="."><plain>B. ,  Christofolini, D. </plain></SENT>
<SENT sid="129" pm="."><plain>M. ,  Dos Santos, A. </plain></SENT>
<SENT sid="130" pm="."><plain>A. ,  Bianco, B. , &amp;  Barbosa, C. </plain></SENT>
<SENT sid="131" pm="."><plain>P.  (2011). Genetic aspects of premature ovarian failure: A literature review. Archives of Gynecology and Obstetrics, 283, 635–643. 10.1007/s00404-010-1815-4 21188402 </plain></SENT>
</text></ref><ref id="mgg3425-bib-0006"><text><SENT sid="132" pm="."><plain>  Fimiani, G. ,  Laperuta, C. ,  Falco, G. ,  Ventruto, V. ,  D'Urso, M. ,  Ursini, M. </plain></SENT>
<SENT sid="133" pm="."><plain>V. , &amp;  Miano, M. </plain></SENT>
<SENT sid="134" pm="."><plain>G.  (2006). Heterozygosity mapping by quantitative fluorescent PCR reveals an interstitial deletion in Xq26.2‐q28 associated with ovarian dysfunction. Human Reproduction, 21, 529–535. 10.1093/humrep/dei356 16239311 </plain></SENT>
</text></ref><ref id="mgg3425-bib-0007"><text><SENT sid="135" pm="."><plain>  Helle, J. </plain></SENT>
<SENT sid="136" pm="."><plain>R. ,  Baroy, T. ,  Misceo, D. ,  Braaten, Ø. ,  Fannemel, M. , &amp;  Frengen, E.  (2013). Hyperphagia, mild developmental delay but apparently no structural brain anomalies in a boy without SOX3 expression. American Journal of Medical Genetics. </plain></SENT>
<SENT sid="137" pm="."><plain>Part A, 161A, 1137–1142. 10.1002/ajmg.a.35823 23463539 </plain></SENT>
</text></ref><ref id="mgg3425-bib-0008"><text><SENT sid="138" pm="."><plain>  Johnson, B. </plain></SENT>
<SENT sid="139" pm="."><plain>A. ,  van Diggelen, O. </plain></SENT>
<SENT sid="140" pm="."><plain>P. ,  Dajnoki, A. , &amp;  Bodamer, O. </plain></SENT>
<SENT sid="141" pm="."><plain>A.  (2013). Diagnosing lysosomal storage disorders: Mucopolysaccharidosis type II. Current Protocols in Human Genetics, 79, 17.14.1–17.14.9. </plain></SENT>
</text></ref><ref id="mgg3425-bib-0009"><text><SENT sid="142" pm="."><plain>  Jourdy, Y. ,  Chatron, N. ,  Carage, M. </plain></SENT>
<SENT sid="143" pm="."><plain>L. ,  Fretigny, M. ,  Meunier, S. ,  Zawadzki, C. ,…  Vinciguerra, C.  (2016). Study of six patients with complete F9 deletion characterized by cytogenetic microarray: Role of the SOX3 gene in intellectual disability. Journal of Thrombosis and Haemostasis, 14, 1988–1993. 10.1111/jth.13430 27477789 </plain></SENT>
</text></ref><ref id="mgg3425-bib-0010"><text><SENT sid="144" pm="."><plain>  Konkle, B. </plain></SENT>
<SENT sid="145" pm="."><plain>A. ,  Josephson, N. </plain></SENT>
<SENT sid="146" pm="."><plain>C. , &amp;  Nakaya Fletcher, S.  (1993). Hemophilia B. </plain></SENT>
</text></ref><ref id="mgg3425-bib-0011"><text><SENT sid="147" pm="."><plain>  Li, T. ,  Miller, C. </plain></SENT>
<SENT sid="148" pm="."><plain>H. ,  Payne, A. </plain></SENT>
<SENT sid="149" pm="."><plain>B. , &amp;  Craig Hooper, W.  (2013). The CDC Hemophilia B mutation project mutation list: A new online resource. Molecular Genetics and Genomic Medicine, 1, 238–245. 10.1002/mgg3.30 24498619 </plain></SENT>
</text></ref><ref id="mgg3425-bib-0012"><text><SENT sid="150" pm="."><plain>  Mercer, C. </plain></SENT>
<SENT sid="151" pm="."><plain>L. ,  Lachlan, K. ,  Karcanias, A. ,  Affara, N. ,  Huang, S. ,  Jacobs, P. </plain></SENT>
<SENT sid="152" pm="."><plain>A. , &amp;  Thomas, N. </plain></SENT>
<SENT sid="153" pm="."><plain>S.  (2013). Detailed clinical and molecular study of 20 females with Xq deletions with special reference to menstruation and fertility. European Journal of Medical Genetics, 56, 1–6. 10.1016/j.ejmg.2012.08.012 23059468 </plain></SENT>
</text></ref><ref id="mgg3425-bib-0013"><text><SENT sid="154" pm="."><plain>  Moore, S. </plain></SENT>
<SENT sid="155" pm="."><plain>J. ,  Strain, L. ,  Cole, G. </plain></SENT>
<SENT sid="156" pm="."><plain>F. ,  Miedzybrodzka, Z. ,  Kelly, K. </plain></SENT>
<SENT sid="157" pm="."><plain>F. , &amp;  Dean, J. </plain></SENT>
<SENT sid="158" pm="."><plain>C.  (1999). Fragile X syndrome with FMR1 and FMR2 deletion. Journal of Medical Genetics, 36, 565–566.10424820 </plain></SENT>
</text></ref><ref id="mgg3425-bib-0014"><text><SENT sid="159" pm="."><plain>  Nisen, P. </plain></SENT>
<SENT sid="160" pm="."><plain>D. , &amp;  Waber, P. </plain></SENT>
<SENT sid="161" pm="."><plain>G.  (1989). Nonrandom X chromosome DNA methylation patterns in hemophiliac females. Journal of Clinical Investigation, 83, 1400–1403. 10.1172/JCI114028 2564852 </plain></SENT>
</text></ref><ref id="mgg3425-bib-0015"><text><SENT sid="162" pm="."><plain>  Orstavik, K. </plain></SENT>
<SENT sid="163" pm="."><plain>H. ,  Scheibel, E. ,  Ingerslev, J. , &amp;  Schwartz, M.  (2000). Absence of correlation between X chromosome inactivation pattern and plasma concentration of factor VIII and factor IX in carriers of haemophilia A and B. Thrombosis and Haemostasis, 83, 433–437. 10.1038/ng1309 10744150 </plain></SENT>
</text></ref><ref id="mgg3425-bib-0016"><text><SENT sid="164" pm="."><plain>  Rizzoti, K. ,  Brunelli, S. ,  Carmignac, D. ,  Thomas, P. </plain></SENT>
<SENT sid="165" pm="."><plain>Q. ,  Robinson, I. </plain></SENT>
<SENT sid="166" pm="."><plain>C. , &amp;  Lovell‐Badge, R.  (2004). OX3 is required during the formation of the hypothalamo‐pituitary axis. Nature Genetics, 36, 247–255.14981518 </plain></SENT>
</text></ref><ref id="mgg3425-bib-0017"><text><SENT sid="167" pm="."><plain>  Sahoo, T. ,  Theisen, A. ,  Marble, M. ,  Thomas, P. </plain></SENT>
<SENT sid="168" pm="."><plain>Q. ,  Robinson, I. </plain></SENT>
<SENT sid="169" pm="."><plain>C. , &amp;  Lovell‐Badge, R.  (2011). Microdeletion of Xq28 involving the AFF2 (FMR2) gene in two unrelated males with developmental delay. American Journal of Medical Genetics. </plain></SENT>
<SENT sid="170" pm="."><plain>Part A, 155A, 3110–3115. 10.1002/ajmg.a.34345 22065534 </plain></SENT>
</text></ref><ref id="mgg3425-bib-0018"><text><SENT sid="171" pm="."><plain>  Sommer, S. </plain></SENT>
<SENT sid="172" pm="."><plain>S. ,  Scaringe, W. </plain></SENT>
<SENT sid="173" pm="."><plain>A. , &amp;  Hill, K. </plain></SENT>
<SENT sid="174" pm="."><plain>A.  (2001). Human germline mutation in the factor IX gene. Mutation Research, 487(1–2), 1–17.11595404 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
